438 words · auto-generated from the episode video
47:19Yeah. Yeah. I mean, it's an incredible paper. And then finally the last sort of visual that I wanted to talk to you about was, um, the recent hashtag hope for liver 2024 paper. Um, this, what we're looking at is, uh, hepatocellular carcinoma on an MRI scan. There's a before and immediately after histotripsy. And then I think this is, uh, 30 days after histotripsy. And you're missing one year. Yeah. Yeah. Well, there's a, there's a one year. Oh, there is a one year. Okay. So I, I think I got this from your paper. It's even newer. Oh, it's an, it's an even newer paper. Okay. Yeah. Um, I think this was the, the first one and maybe, maybe it was there,
48:02but I got like the free version on NCBI website. You had, there's a 30 day follow-up paper. Then there's a year follow-up paper. So the year follow-up paper is very recent. Oh, it's very recent. Yeah. Very recent. And, uh, and it's, uh, uh, so this is, uh, the multi central clinical trial that led to the FDA approval for non-invasive histotripsy treatment of tumors in the liver. Yeah. Uh, and the showing, uh, that why is safe. So the site, the adverse events reach is very, very low. And the second is, uh, uh, you can see on the MRI, uh, scan that the, the tumor they
48:42treat, the reason the abrasion zone is large is because, uh, clinicians always want to treat with a margin, right? Cause there's always cancer cells you can't see. Yeah. Like it didn't show up in the MRI. So they want to really make sure you, you reach everything, but that histotripsy treatment region, uh, like this kind of liquid get absorbed by the body pretty fast. So if you see 30 days already shrinking substantially in one year, it's like the tumor is surgically reset. It's gone. Oh, so, so I would imagine there it's like, it looks like normal liver tissue. Yeah, pretty much. So, uh, so at the, uh, 30 days follow up the technical
49:23success reach on imaging, meaning that the clinician can confirm on imaging that this is a region, and that I treat this region successfully, it's like 96%. And when you follow up the local tumor control rate, meaning that you actually, you know, you killed it, uh, it's 90%. So, which is a very good result. So really another thing about this is that because it's non-invasive, so it's like, not like surgeon can go in and cut it and see everything directly in their own eyes.